Published in Annu Rev Immunol on January 01, 2009
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A (2010) 8.05
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol (2012) 5.86
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
Morbidity and mortality in common variable immune deficiency over 4 decades. Blood (2011) 3.18
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther (2011) 2.48
Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity (2010) 2.47
Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. Nat Immunol (2009) 2.29
CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest (2010) 1.79
Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol (2011) 1.76
B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol (2013) 1.72
Reference values for B cell subpopulations from infancy to adulthood. Clin Exp Immunol (2010) 1.70
Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K. J Exp Med (2012) 1.66
The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol (2009) 1.57
Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood (2012) 1.45
Genetic lessons learned from X-linked Mendelian susceptibility to mycobacterial diseases. Ann N Y Acad Sci (2011) 1.43
Human Adaptive Immunity Rescues an Inborn Error of Innate Immunity. Cell (2017) 1.41
Intravenous immunoglobulins--understanding properties and mechanisms. Clin Exp Immunol (2009) 1.34
The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol (2012) 1.25
Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses. Crit Rev Immunol (2010) 1.22
Primary antibody deficiencies. Nat Rev Immunol (2013) 1.20
Clinical consequences of defects in B-cell development. J Allergy Clin Immunol (2010) 1.19
The cytoskeleton coordinates the early events of B-cell activation. Cold Spring Harb Perspect Biol (2011) 1.17
Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J Exp Med (2013) 1.14
The many faces of common variable immunodeficiency. Hematology Am Soc Hematol Educ Program (2012) 1.12
Laboratory evaluation of primary immunodeficiencies. J Allergy Clin Immunol (2009) 1.10
Perspectives on common variable immune deficiency. Ann N Y Acad Sci (2011) 1.09
B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C δ. Blood (2013) 1.02
Genetics of SCID. Ital J Pediatr (2010) 1.02
Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies. Cancer Manag Res (2013) 1.01
Clinical characteristics and genotype-phenotype correlation in 62 patients with X-linked agammaglobulinemia. J Clin Immunol (2009) 1.00
TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow. Blood (2011) 1.00
The regulation and role of T follicular helper cells in immunity. Immunology (2011) 0.99
B cell TLRs and induction of immunoglobulin class-switch DNA recombination. Front Biosci (Landmark Ed) (2012) 0.99
Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100. Blood (2014) 0.99
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol (2014) 0.97
A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR(-) B cells. J Clin Invest (2013) 0.96
IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. Haematologica (2009) 0.94
Human genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathway. PLoS Genet (2013) 0.93
Enhancer-promoter communication and transcriptional regulation of Igh. Trends Immunol (2011) 0.92
Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species. J Allergy Clin Immunol (2012) 0.90
Genetics of hypogammaglobulinemia: what do we really know? Curr Opin Immunol (2009) 0.90
B-lymphocyte lineage cells and the respiratory system. J Allergy Clin Immunol (2013) 0.89
PID comes full circle: applications of V(D)J recombination excision circles in research, diagnostics and newborn screening of primary immunodeficiency disorders. Front Immunol (2011) 0.89
Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid (2013) 0.87
B-cell subpopulations in children: National reference values. Immun Inflamm Dis (2014) 0.86
Naïve and memory B cells in the rhesus macaque can be differentiated by surface expression of CD27 and have differential responses to CD40 ligation. J Immunol Methods (2010) 0.86
Application of whole genome and RNA sequencing to investigate the genomic landscape of common variable immunodeficiency disorders. Clin Immunol (2015) 0.86
Primary immunodeficiency. Allergy Asthma Clin Immunol (2011) 0.86
Nucleosome stability dramatically impacts the targeting of somatic hypermutation. Mol Cell Biol (2012) 0.85
Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency. Clin Exp Immunol (2015) 0.83
Changes in RNA polymerase II progression influence somatic hypermutation of Ig-related genes by AID. J Exp Med (2013) 0.83
Decline of antibodies in XLA infant: when to start IVIG. Allergy (2010) 0.83
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol (2015) 0.83
CD19 controls Toll-like receptor 9 responses in human B cells. J Allergy Clin Immunol (2015) 0.82
Activation of Ras overcomes B-cell tolerance to promote differentiation of autoreactive B cells and production of autoantibodies. Proc Natl Acad Sci U S A (2014) 0.81
Physiological IgM class catalytic antibodies selective for transthyretin amyloid. J Biol Chem (2014) 0.81
A custom 148 gene-based resequencing chip and the SNP explorer software: new tools to study antibody deficiency. Hum Mutat (2010) 0.81
Relevance of laboratory testing for the diagnosis of primary immunodeficiencies: a review of case-based examples of selected immunodeficiencies. Clin Mol Allergy (2011) 0.81
Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis. Cold Spring Harb Perspect Med (2014) 0.80
Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis (2014) 0.80
Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. J Clin Invest (2014) 0.80
Splice-correction strategies for treatment of X-linked agammaglobulinemia. Curr Allergy Asthma Rep (2015) 0.80
Ibrutinib (PCI-32765) in chronic lymphocytic leukemia. Hematol Oncol Clin North Am (2013) 0.79
Autosomal recessive agammaglobulinemia: a novel non-sense mutation in CD79a. J Clin Immunol (2014) 0.78
Monozygotic twins discordant for common variable immunodeficiency reveal impaired DNA demethylation during naïve-to-memory B-cell transition. Nat Commun (2015) 0.78
N-3 polyunsaturated fatty acids modulate B cell activity in pre-clinical models: Implications for the immune response to infections. Eur J Pharmacol (2015) 0.78
Proteomic changes during B cell maturation: 2D-DIGE approach. PLoS One (2013) 0.78
IgH sequences in common variable immune deficiency reveal altered B cell development and selection. Sci Transl Med (2015) 0.77
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. Leukemia (2016) 0.77
Parental consanguinity is associated with a severe phenotype in common variable immunodeficiency. J Clin Immunol (2011) 0.77
Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen. AIDS (2014) 0.77
Successful approach to treatment of Helicobacter bilis infection in X-linked agammaglobulinemia. J Clin Immunol (2012) 0.77
Novel sequencing-based strategies for high-throughput discovery of genetic mutations underlying inherited antibody deficiency disorders. Curr Allergy Asthma Rep (2011) 0.77
Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase. Sci Rep (2016) 0.76
Enteroviral Infection in a Patient with BLNK Adaptor Protein Deficiency. J Clin Immunol (2015) 0.76
Btk29A-mediated tyrosine phosphorylation of armadillo/β-catenin promotes ring canal growth in Drosophila oogenesis. PLoS One (2015) 0.75
Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition. Cardiovasc Hematol Agents Med Chem (2013) 0.75
From identification of the BTK kinase to effective management of leukemia. Oncogene (2016) 0.75
Lung Disease in Primary Antibody Deficiencies. J Allergy Clin Immunol Pract (2016) 0.75
Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib. Ther Adv Hematol (2016) 0.75
Clinical characteristics and genetic profiles of 174 patients with X-linked agammaglobulinemia: Report from Shanghai, China (2000-2015). Medicine (Baltimore) (2016) 0.75
Deficit of Anterior Pituitary Function and Variable Immune Deficiency Syndrome: A Novel Mutation. Glob Pediatr Health (2017) 0.75
Atypical X-linked agammaglobulinaemia caused by a novel BTK mutation in a selective immunoglobulin M deficiency patient. BMC Pediatr (2013) 0.75
The Production Processes and Biological Effects of Intravenous Immunoglobulin. Biomolecules (2016) 0.75
Differential gene expression analysis by RNA-seq reveals the importance of actin cytoskeletal proteins in erythroleukemia cells. PeerJ (2017) 0.75
Autosomal recessive agammaglobulinemia due to defect in μ heavy chain caused by a novel mutation in the IGHM gene. Genes Immun (2017) 0.75
Autosomal recessive agammaglobulinemia: the third case of Igβ deficiency due to a novel non-sense mutation. J Clin Immunol (2014) 0.75
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76
A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics (2012) 3.10
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 2.81
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood (2009) 2.70
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2012) 2.55
Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res (2010) 2.51
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res (2009) 2.37
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood (2007) 2.19
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood (2012) 2.14
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05
The actin regulator coronin 1A is mutant in a thymic egress-deficient mouse strain and in a patient with severe combined immunodeficiency. Nat Immunol (2008) 1.97
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood (2011) 1.88
New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2011) 1.78
Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood (2002) 1.74
Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol (2011) 1.71
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood (2013) 1.70
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood (2011) 1.68
A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy (2012) 1.67
Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K. J Exp Med (2012) 1.66
Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.53
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol (2011) 1.52
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood (2010) 1.47
An Artemis polymorphic variant reduces Artemis activity and confers cellular radiosensitivity. DNA Repair (Amst) (2010) 1.46
Severe combined immunodeficiency (SCID) and attention deficit hyperactivity disorder (ADHD) associated with a Coronin-1A mutation and a chromosome 16p11.2 deletion. Clin Immunol (2008) 1.46
HAE international home therapy consensus document. Allergy Asthma Clin Immunol (2010) 1.42
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood (2005) 1.42
Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol (2003) 1.41
Genetic analysis of patients with defects in early B-cell development. Immunol Rev (2005) 1.41
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood (2006) 1.41
A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood (2006) 1.40
Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol (2005) 1.35
Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol (2003) 1.33
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol (2014) 1.31
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood (2004) 1.30
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol (2012) 1.30
Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol (2012) 1.29
Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood (2002) 1.28
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy (2012) 1.27
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One (2011) 1.23
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst (2011) 1.23
Replicative potential of human natural killer cells. Br J Haematol (2009) 1.19
Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol (2010) 1.19
Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. J Pediatr (2002) 1.16
Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol (2010) 1.16
2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res (2009) 1.15
Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther (2006) 1.13
Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15. Br J Haematol (2011) 1.10
Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood (2010) 1.10
Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma (2009) 1.07
Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group. J Clin Oncol (2009) 1.06
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica (2012) 1.05
A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res (2013) 1.02
Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Exp Hematol (2007) 1.02
Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med (2009) 1.02
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother (2015) 1.01
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther (2011) 1.00
A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids (2013) 0.99
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer (2013) 0.98
T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res (2013) 0.98
Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica (2006) 0.98
Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer (2008) 0.95
Adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine (Baltimore) (2008) 0.94
Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol (2002) 0.94
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics (2011) 0.93
Should evaluation for minimal residual disease be routine in acute myeloid leukemia? Curr Opin Hematol (2013) 0.92
Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. Int J Data Min Bioinform (2011) 0.91